Daniel Stauder
Stock Analyst at Citizens
(3.17)
# 1,144
Out of 5,150 analysts
23
Total ratings
45.45%
Success rate
6.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LMAT LeMaitre Vascular | Maintains: Market Outperform | $113 → $118 | $106.41 | +10.89% | 5 | Feb 26, 2026 | |
| ATRC AtriCure | Maintains: Market Outperform | $60 → $52 | $30.99 | +67.80% | 7 | Feb 18, 2026 | |
| STXS Stereotaxis | Initiates: Market Outperform | $4 | $2.20 | +81.82% | 1 | Dec 16, 2025 | |
| AORT Artivion | Maintains: Market Outperform | $47 → $53 | $38.50 | +37.66% | 7 | Nov 7, 2025 | |
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $1.33 | +426.32% | 1 | Mar 5, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $569.81 | +27.24% | 1 | Feb 26, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $13.88 | - | 1 | May 7, 2024 |
LeMaitre Vascular
Feb 26, 2026
Maintains: Market Outperform
Price Target: $113 → $118
Current: $106.41
Upside: +10.89%
AtriCure
Feb 18, 2026
Maintains: Market Outperform
Price Target: $60 → $52
Current: $30.99
Upside: +67.80%
Stereotaxis
Dec 16, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.20
Upside: +81.82%
Artivion
Nov 7, 2025
Maintains: Market Outperform
Price Target: $47 → $53
Current: $38.50
Upside: +37.66%
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $1.33
Upside: +426.32%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $569.81
Upside: +27.24%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $13.88
Upside: -